Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaques.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Haplotypes/*immunology ; Macaca/*immunology ; Macaca fascicularis/*immunology ; Major Histocompatibility Complex/*genetics ; Major Histocompatibility Complex/*immunology ; Simian Acquired Immunodeficiency Syndrome/*immunology ; Simian Immunodeficiency Virus/*immunology; Animals ; Antibodies, Neutralizing/genetics ; CD4-Positive T-Lymphocytes/immunology ; HIV/immunology ; Haplotypes/genetics ; Interleukin-10/genetics ; Interleukin-10/immunology ; Macaca/genetics ; Macaca/virology ; Macaca fascicularis/genetics ; Male ; RNA, Viral/genetics ; RNA, Viral/immunology ; Simian Acquired Immunodeficiency Syndrome/genetics ; Simian Acquired Immunodeficiency Syndrome/virology ; Viral Load/genetics ; Viral Load/immunology ; alpha-Defensins/genetics

Little is known about the effects of Major Histocompatibility Complex (MHC) haplotypes on immunity to primate lentiviruses involving both acquired and innate immune responses. We present statistical evidence of the influence of MHC polymorphism on antiviral immunity of Mauritian cynomolgus macaques (MCM) following simian/human immunodeficiency virus SHIVSF162P4cy infection, involving the production of pro- and anti-inflammatory cytokines and α-defensins, which may modulate acquired immune responses. During the acute phase of infection, IL-10 correlated positively with viral load and negatively with CD4+T cell counts. Furthermore, α-defensins production was directly correlated with plasma viral RNA, particularly at peak of viral load. When the effects of the MHC were analyzed, a significant association between lower anti-Env binding and neutralizing antibody levels with class IB M4 haplotype and with class IA, IB M4 haplotype, respectively, was observed in the post-acute phase. Lower antibody responses may have resulted into a poor control of infection thus explaining the previously reported lower CD4 T cell counts in these monkeys. Class II M3 haplotype displayed significantly lower acute and post-acute IL-10 levels. In addition, significantly lower levels of α-defensins were detected in class IA M3 haplotype monkeys than in non-M3 macaques, in the post-acute phase of infection. These data indicate that the MHC could contribute to the delicate balance of pro-inflammatory mechanisms, particularly with regard to the association between IL-10 and α-defensins in lentivirus infection. Our results show that host genetic background, virological and immunological parameters should be considered for the design and interpretation of HIV-1 vaccine efficacy studies.

J Immunol. 2002 Sep 15;169(6):3438-46. (PMID: 12218167)
Cell Host Microbe. 2012 Jul 19;12(1):109-16. (PMID: 22817992)
Expert Rev Vaccines. 2003 Apr;2(2):285-93. (PMID: 12899578)
AIDS Res Hum Retroviruses. 2007 Feb;23(2):287-96. (PMID: 17331035)
J Virol. 2010 Jul;84(14):7083-95. (PMID: 20463069)
Tissue Antigens. 2009 Apr;73(4):289-301. (PMID: 19317737)
J Infect Dis. 2000 Sep;182(3):716-24. (PMID: 10950764)
AIDS Rev. 2004 Oct-Dec;6(4):187-98. (PMID: 15700617)
Genes Immun. 2009 Jun;10(4):309-22. (PMID: 19295541)
AIDS Res Hum Retroviruses. 2011 Jun;27(6):639-46. (PMID: 20969482)
Retrovirology. 2012 Sep 20;9:76. (PMID: 22995123)
Cell Host Microbe. 2012 Jul 19;12(1):5-7. (PMID: 22817983)
J Virol. 1997 Dec;71(12):9508-14. (PMID: 9371613)
Clin Exp Immunol. 1999 Apr;116(1):115-20. (PMID: 10209514)
AIDS. 2003 Sep 26;17(14):F23-32. (PMID: 14502030)
J Virol. 2008 Jan;82(2):859-70. (PMID: 17989178)
PLoS One. 2010 Mar 17;5(3):e9737. (PMID: 20305815)
J Virol. 2007 Jan;81(1):406-10. (PMID: 17079280)
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):6-16. (PMID: 16340467)
J Immunol. 2009 Feb 1;182(3):1439-48. (PMID: 19155491)
Eur Cytokine Netw. 2010 Sep;21(3):219-21. (PMID: 20719708)
Tissue Antigens. 2012 Jul;80(1):36-45. (PMID: 22494179)
Immunity. 2012 Sep 21;37(3):389-98. (PMID: 22999945)
Immunogenetics. 2011 May;63(5):267-74. (PMID: 21234560)
J Pathol. 2008 Jan;214(2):224-30. (PMID: 18161757)
Immunogenetics. 2009 May;61(5):327-39. (PMID: 19337730)
Heredity (Edinb). 2006 Jan;96(1):7-21. (PMID: 16094301)
Eur Cytokine Netw. 2010 Sep;21(3):208-14. (PMID: 20732847)
Arch Virol. 2008;153(3):463-72. (PMID: 18080858)
Immunol Lett. 2011 Jun 30;137(1-2):1-8. (PMID: 21262263)
J Infect Dis. 2009 Aug 1;200(3):448-52. (PMID: 19534595)
AIDS Res Hum Retroviruses. 2006 Aug;22(8):757-62. (PMID: 16910831)
Immunogenetics. 2010 Dec;62(11-12):773-80. (PMID: 20882385)
Blood. 2007 Apr 1;109(7):2928-35. (PMID: 17132727)
Vaccine. 2011 Apr 5;29(16):2918-32. (PMID: 21338681)
Immunol Lett. 1999 Mar;66(1-3):53-9. (PMID: 10203034)
J Immunol. 2011 Feb 1;186(3):1589-97. (PMID: 21178012)
AIDS. 2012 Jun 19;26(10):1269-79. (PMID: 22472855)
Tissue Antigens. 2010 Sep;76(3):223-9. (PMID: 20403147)
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8. (PMID: 8990195)
Mol Immunol. 2005 Feb;42(2):251-8. (PMID: 15488612)
J Virol. 2003 Feb;77(3):2165-73. (PMID: 12525651)
Science. 2002 May 24;296(5572):1439-43. (PMID: 12029127)

0 (Antibodies, Neutralizing)
0 (RNA, Viral)
0 (alpha-Defensins)
130068-27-8 (Interleukin-10)

Date Created: 20140404 Date Completed: 20150120 Latest Revision: 20211021

20221213

PMC3973703

10.1371/journal.pone.0093235

24695530